These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28019139)

  • 1. Individual luteolysis post GnRH-agonist-trigger in GnRH-antagonist protocols.
    Lawrenz B; Ruiz F; Engelmann N; Fatemi HM
    Gynecol Endocrinol; 2017 Apr; 33(4):261-264. PubMed ID: 28019139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GnRH agonist versus HCG triggering in different IVF/ICSI cycles of same patients: a retrospective study.
    Yılmaz N; Ceran MU; Ugurlu EN; Gülerman HC; Engin Ustun Y
    J Obstet Gynaecol; 2020 Aug; 40(6):837-842. PubMed ID: 31791167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of luteal phase defect and spontaneous pregnancy in IVF patients despite GnRH-agonist trigger and "freeze all policy" without luteal phase support: a report of four cases.
    Gurbuz AS; Deveer R; Ozcimen N; Ozcimen EE; Lawrenz B; Banker M; Garcia-Velasco JA; Fatemi HM
    Gynecol Endocrinol; 2016; 32(1):18-20. PubMed ID: 26487486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individual luteolysis pattern after GnRH-agonist trigger for final oocyte maturation.
    Lawrenz B; Garrido N; Samir S; Ruiz F; Melado L; Fatemi HM
    PLoS One; 2017; 12(5):e0176600. PubMed ID: 28459828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
    Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
    J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRH-agonist triggering for final oocyte maturation in GnRH-antagonist IVF cycles induces decreased LH pulse rate and amplitude in early luteal phase: a possible luteolysis mechanism.
    Tannus S; Burke Y; McCartney CR; Kol S
    Gynecol Endocrinol; 2017 Sep; 33(9):741-745. PubMed ID: 28440715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
    Elgindy EA; Sibai H; Mostafa MI; Gibreel A; Darwish E; Maghraby H
    Hum Reprod; 2018 Jun; 33(6):1079-1086. PubMed ID: 29562260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteal granulosa cells from natural cycles are more capable of maintaining their viability, steroidogenic activity and LH receptor expression than those of stimulated IVF cycles.
    Bildik G; Akin N; Seyhan A; Esmaeilian Y; Yakin K; Keles I; Balaban B; Ata B; Urman B; Oktem O
    Hum Reprod; 2019 Feb; 34(2):345-355. PubMed ID: 30520979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-administration of GnRH-agonist and hCG (double trigger) for final oocyte maturation increases the number of top-quality embryos in patients undergoing IVF/ICSI cycles.
    Tu B; Zhang H; Chen L; Yang R; Liu P; Li R; Qiao J
    J Ovarian Res; 2024 Jul; 17(1):137. PubMed ID: 38961417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
    Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
    Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
    Orvieto R
    J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotropin Releasing Hormone Agonist Final Oocyte Maturation and Human Chorionic Gonadotropin as Exclusive Luteal Support in Normal Responders.
    Beck-Fruchter R; Baram S; Geslevich Y; Weiss A
    Gynecol Obstet Invest; 2019; 84(1):27-34. PubMed ID: 30048969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luteal phase serum progesterone levels after GnRH-agonist trigger - how low is still high enough for an ongoing pregnancy?
    Lawrenz B; Samir S; Melado L; Ruiz F; Fatemi HM
    Gynecol Endocrinol; 2018 Mar; 34(3):195-198. PubMed ID: 29037085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Rationale for Timing of Luteal Support Post Gonadotropin-Releasing Hormone Agonist Trigger.
    Kol S
    Gynecol Obstet Invest; 2019; 84(1):1-5. PubMed ID: 30007966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.